Belyntic develops novel immunotherapeutic candidates using a modular approach focused on T cell responses. The company utilizes its T-Fender platform technology, based on synthetic long peptides, to create therapeutic and prophylactic vaccines. These vaccines induce potent, pathogen-specific cellular immune responses against viral and bacterial infections through an AI-powered design process.
Funding
$811.1K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccines often prioritize antibody production, neglecting the importance of T cell-mediated immunity, which is crucial for combating existing viral infections and providing long-term protection against reactivation, especially in vulnerable patients. Existing treatments for latent viral infections with limited options can result in low survival rates and significant health complications.
Solution
Belyntic develops immunotherapies, specifically T cell-inducing vaccines, for individuals at risk of or affected by viral and bacterial infectious diseases. The company's T-Fender platform utilizes self-adjuvant synthetic long peptides (SLPs) designed to trigger robust and enduring cellular immune responses. These SLPs integrate MHC class I and class II epitopes, along with enzymatic cleavage sites, to ensure the precise release of active components. The vaccines are adaptable using AI-based prediction technology and are designed for straightforward manufacturing and formulation.
Target Audience
The primary target audience includes individuals afflicted by infectious diseases or those at significant risk of contracting them, particularly immunocompromised individuals and vulnerable patients such as solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.
Features
- T-Fender platform technology based on self-adjuvant, self-aggregating synthetic long peptides.
- Prime/boost vaccination approach to trigger robust and enduring cellular immune responses.
- AI-powered development for rapid design of novel vaccine candidates.
- Focus on inducing pathogen-specific T cells with a lasting memory effect.
- Stable inherent formulation with enhanced stability for facilitated application.
- Modular design integrating MHC class I and class II epitopes.